Business Context and Reporting Period
This Form 8-K is a current report filed by AcelRx Pharmaceuticals, Inc. (not TalpherA, Inc. as indicated in metadata) on February 7, 2012. The report discloses corporate governance actions taken by the Board of Directors regarding executive compensation, effective retroactively to January 1, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
| Named Executive Officer | 2012 Base Salary | 2011 Bonus Payment |
|---|---|---|
| Richard A. King, CEO | $426,006 | $100,842 |
| James H. Welch, CFO | $299,000 | $67,425 |
| Pamela P. Palmer, CMO | $396,550 | $89,513 |
| Lawrence G. Hamel, CDO | $292,800 | $70,892 |
| Badri Dasu, CEO (Engineering) | $278,000 | $59,645 |
Material Changes
The Board approved 2012 base salaries for five Named Executive Officers (NEOs), effective retroactively to January 1, 2012. Additionally, the Board approved 2011 performance bonus payments for the same NEOs in accordance with the Company's established 2011 Cash Bonus Plan. No prior period salary data is provided in this text for direct comparison.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, risk factors, or discussion of contingencies. The document is limited to the disclosure of specific compensatory arrangements approved by the Board.
Investor Verification Checklist
- Verify the total cash compensation impact on the company's operating expenses for 2012.
- Confirm the performance metrics used to calculate the 2011 bonuses under the Cash Bonus Plan.
- Review the company's cash position to ensure liquidity is sufficient to cover these approved payments.
- Check for any related party transactions or conflicts of interest regarding the Board's approval of these salaries.